FindTrial
Sign In

Treatment benefit of prednisolone in hump-nosed viper bite in Sri Lanka

Reducing local and systemic envenoming in hump-nosed viper bite by treating early with oral prednisolone: randomised, double blind trial in Sri Lanka

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2011/012
Enrollment
Unknown
Registered
2011-11-25
Start date
2011-11-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hump- nosed viper envenoming

Interventions

Treatment arms Group A Oral prednisolone 40 mg daily for 2 days Group B Nil

Sponsors

Prof. SAM Kularatne
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients with proven hump-nosed pit viper bites • Older than 12 years of age

Exclusion criteria

Exclusion criteria: • Patient who has received extended course of steroids within one month or currently receiving prednisolone, hydrocortisone, antihistamine treatments. • Evidence of bacterial infection at the bitten site • Patients with any febrile condition or with evidence of an infection • Chronic medical problems

Design outcomes

Primary

MeasureTime frame
Severity of local envenoming, including assessment of 1. Pain 2. Local swelling 3. Local discolouration 4. Requirement of surgical interventions 5. Length of hospital stay due to local envenoming [Twice daily until discharge from the hospital]—

Secondary

MeasureTime frame
Severity of systemic envenoming, including 1. Length of hospital stay due to systemic envenoming 2. Incidence of complications (ARF, DIC, coagulopathy) 3. Death [Twice daily until discharge from the hospital]—

Countries

Sri Lanka

Contacts

Public ContactProf. SAM Kularatne
samkul@sltnet.lk081 2388369

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026